Andreia de Albuquerque

Dr. Andreia de Albuquerque joined Invivoscribe in 2015 and currently serves as the Director of Business Development. In this role, she is responsible for leading Invivoscribe’s global partnerships with Pharma and Biotech, focusing on companion diagnostics development, custom assay development, clinical trial testing, corporate partnerships, and other strategic relationships.

Prior to joining Invivoscribe, Dr. de Albuquerque has held roles in precision molecular diagnostics, focusing on the development, implementation, and validation of PCR and NGS assays for diagnostic and research purposes. Her work has resulted in several peer-reviewed publications and participation in international conferences. During this time, she was also responsible for overseeing laboratory diagnostic teams and operations.

Her extensive expertise in precision diagnostics and understanding of assay development and clinical testing paved the way into Business Development, where she focused on accelerating drug approvals, by building successful partnerships, providing technical expertise, and working closely with biomarker leaders, sample operations, clinical science, and regulatory to implement CDx, IVD and R&D assays in clinical trials.

Dr. de Albuquerque earned her degree in Biology from the University of Coimbra (Portugal) and a combined Ph.D. in Oncology and Molecular Biology from the University of Dresden (Germany).